AUS
NZ
UK
CA
USA
IND
As the market evolves, certain companies are catching investors' attention with their impressive performance. ResMed CDI and Netwealth Group Ltd have recently made notable strides, reflecting their strong positions in their respective sectors. ResMed’s share price has surged significantly this year, while Netwealth's resilience stands out despite market fluctuations. Additionally, an ASX value stock has been showing strong performance. This article explores the factors behind their recent successes and what they mean for future investment prospects.
ResMed (ASX:RMD)
ResMed CDI has experienced an impressive 44.3% increase in its share price since the beginning of 2024. This surge reflects strong performance and growing investor confidence in the company.
Founded in 1989 by Peter Farrell, ResMed started in Australia and is now headquartered in San Diego, California. The company specializes in medical equipment, particularly continuous positive airway pressure (CPAP) machines used to treat obstructive sleep apnea (OSA). ResMed’s primary listing is on the NYSE, but it is also traded on the ASX.
Operating globally with over 10,000 employees, ResMed is present in more than 140 countries. The company has two main business segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division offers CPAP machines and other respiratory devices, while the SaaS unit provides software solutions for managing durable or home medical equipment.
ResMed’s cloud-connected devices and extensive digital health network allow the company to gather valuable data, improve patient outcomes, and reduce healthcare costs. Despite the impressive rise in its share price, ResMed's price-to-sales ratio stands at 5.22x, which is below its 5-year average of 6.13x. This suggests that the shares are trading below their historical average.
Netwealth Group (ASX:NWL)
Netwealth Group Ltd has also demonstrated resilience, with its share price currently about 84.2% above its 52-week low. Established in 1999, Netwealth is a wealth management platform offering financial planners a comprehensive tool for managing client investments.
The company’s platform supports over 140,000 account holders and manages more than $88 billion in funds. Netwealth’s user-friendly interface provides clients with a single dashboard to track investments, view performance reports, and manage tax statements.
Both ResMed and Netwealth Group have shown notable performance in recent times. ResMed continues to benefit from its global presence and advanced technology in healthcare, while Netwealth’s robust platform and scale contribute to its resilience. Investors might find both companies worth monitoring given their strong recent performances and the evolving market conditions.
